Table 5.
Multivariate prognostic analyses.
| Parameters | HR | DFS 95% CI | P | HR | OS 95% CI | P |
|---|---|---|---|---|---|---|
| Age | ||||||
| ≤ 60 years | 1 | 1 | ||||
| > 60 years | 0.170 | 0.023–1.232 | 0.079 | 0.523 | 0.116–2.349 | 0.398 |
| Histology | 0.576 | 0.082 | ||||
| Endometrioid carcinoma grade 3 | 1 | 1 | ||||
| Serous carcinoma | 0.899 | 0.250–3.236 | 0.870 | 0.304 | 0.073–1.264 | 0.101 |
| Clear cell carcinoma | 0.679 | 0.124–3.732 | 0.656 | 0.161 | 0.026–1.006 | 0.051 |
| Carcinosarcoma | 0.429 | 0.064–2.868 | 0.383 | 0.292 | 0.046–1.876 | 0.195 |
| Neuroendocrine | 17.720 | 0.398–788.824 | 0.138 | 5.201 | 0.190–142.246 | 0.329 |
| Myometrial invasion | ||||||
| Superficial | 1 | 1 | ||||
| Deep | 4.460 | 0.990–20.095 | 0.052 | 2.138 | 0.534–8.558 | 0.283 |
| Lymph node metastasis | ||||||
| Absent | 1 | 1 | ||||
| Present | 0.310 | 0.063–1.540 | 0.152 | 0.082 | 0.014–0.473 | 0.005 |
| FIGO stage | 0.562 | 0.014 | ||||
| I | 1 | 1 | ||||
| II | 0.362 | 0.059–2.206 | 0.270 | 0.790 | 0.105–5.912 | 0.818 |
| III | 1.126 | 0.193–6.575 | 0.895 | 12.443 | 1.782–86.877 | 0.011 |
| IV | 2.371 | 0.187–29.994 | 0.505 | 24.520 | 2.625–229.027 | 0.005 |
| CA125 (U/mL) at primary diagnosis | ||||||
| ≤ 46.50 | 1 | 1 | ||||
| > 46.50 | 2.632 | 0.666–10.403 | 0.167 | 1.021 | 0.235–4.432 | 0.978 |
| HE4 (pmol/L) at primary diagnosis | ||||||
| ≤ 89.50 | 1 | 1 | ||||
| > 89.50 | 1.400 | 0.356–5.499 | 0.630 | 3.001 | 0.651–13.837 | 0.159 |
| CA125 (U/mL) at recurrence | ||||||
| ≤ 32.45 | 1 | 1 | ||||
| > 32.45 | 7.864 | 2.460–25.144 | 0.001 | 8.835 | 2.521–30.969 | 0.001 |
| HE4 (pmol/L) at recurrence | ||||||
| ≤ 92.50 | 1 | 1 | ||||
| > 92.50 | 15.565 | 2.491–97.251 | 0.003 | 4.493 | 1.047–19.289 | 0.043 |
The total number of events were both 21 for recurrence and death.
HR hazard ratio, CI confidence interval.